Skip to main content

Table 12 SUCRA ranking of the proportion of patients with decline in FVC≥10% predicted

From: A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials

Treatment

SUCRA

PrBest

MeanRank

Ambrisentan

96

84.1

1.2

Placebo

80.4

11.8

2

Nintedanib

41.8

0

3.9

Pirfenidone

40.4

0

4

Warfarin

31.3

3.8

4.4

Pamrevlumab

10.2

0.2

5.5

  1. Higher values of SUCRA indicate that the proportion of patients with decline in FVC ≥ 10% predicted is higher
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us